What do systematic reviews say?

Metoprolol vs placebo

Metoprolol showed no clear difference in all‐cause mortality, 30 days1 compared with placebo (low certainty).

• Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with… 2017 · Cochrane Headline outcomes only
  OR 0.17 [0.02, 1.41]
  1 study · 227 participants
  Low

Summary of findings table ‐ Methylprednisolone vs dexamethasone

It is very uncertain whether summary of findings table ‐ Methylprednisolone changes all‐cause mortality up to 30 days compared with dexamethasone (very low certainty).

• Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes only
  RR 0.51 [0.24, 1.07]
  1 study · 86 participants
  Very low

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).

• Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes only
  RR 0.87 [0.73, 1.04]
  3 studies · 1269 participants
  Low

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

It is very uncertain whether summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) changes all‐cause mortality up to 120 days compared with low‐dose dexamethasone (6 mg to 8 mg) (very low certainty).

• Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes only
  RR 0.93 [0.79, 1.08]
  4 studies · 1383 participants
  Very low

Summary of findings table ‐ Methylprednisolone vs dexamethasone

The review found no eligible studies for this question.

• Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Tranexamic acid vs placebo

• Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 100 participants
  Very low

Summary of findings: Fibrin sealant vs usual care

It is very uncertain whether summary of findings: Fibrin sealant changes all‐cause mortality up to 30 days compared with usual care (very low certainty).

• Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and… 2023 · Cochrane Headline outcomes only
  RR 0.44 [0.11, 1.76]
  3 studies · 585 participants
  Very low

Thromboelastography threshold vs standard of care (laboratory parameters)

The review found no eligible studies for this question.

• Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use undergoing… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found